Related Experiment Video

Updated: Mar 8, 2026

Examining BCL-2 Family Function with Large Unilamellar Vesicles
08:35

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Published on: October 5, 2012

8.4K

Therapeutic inhibition of BCL-2 and related family members

Michelle A Levy1, David F Claxton1

  • 1a Penn State Milton S. Hershey Medical Center , Penn State Hershey Cancer Institute , Hershey , PA , USA.

Expert Opinion on Investigational Drugs
|February 7, 2017
PubMed
Abstract

Insights

Targeting BCL-2 proteins with BH3 mimetics offers a promising strategy to combat cancer by restoring programmed cell death. These therapies are showing significant clinical success in various malignancies.

Area of Science:

  • Molecular Biology
  • Oncology
  • Pharmacology

Background:

  • BCL-2 proteins regulate apoptosis, influencing cancer development and progression.
  • Dysregulation of apoptosis is a hallmark of cancer, enabling tumor cell survival.
  • Targeting BCL-2 family proteins aims to restore cancer cell death.

Purpose of the Study:

  • To review the biology of the intrinsic apoptotic pathway and the roles of BCL-2 family proteins.
  • To discuss BH3 profiling as a method to assess pathway dependency.
  • To explore current and emerging therapeutic strategies targeting BCL-2 family proteins.

Main Methods:

  • Review of existing literature on BCL-2 family biology and apoptosis.
  • Analysis of historical and current BH3 mimetic drugs.
  • Discussion of clinical trial data and expert opinion on targeted therapies.

Main Results:

  • BH3 mimetics, such as venetoclax (ABT-199), are effective in treating hematologic and solid tumors.
  • Understanding BCL-2 family interactions is crucial for developing targeted therapies.
  • Ongoing research focuses on overcoming resistance and targeting other family members like MCL-1.

Conclusions:

  • BH3 mimetics represent a significant advancement in cancer therapy, enhancing apoptosis in malignant cells.
  • The clinical application of BCL-2 targeted agents is expanding, improving patient outcomes.
  • Future directions include developing novel agents and combination therapies for broader efficacy.
Keywords:
BCL-2BH3 mimeticsapoptosistargeted therapy

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.9K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.6K

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K